The development of AXL inhibitors in lung cancer: recent progress and challenges
AXL, along with MER and TYRO3, is a receptor tyrosine kinase from the TAM family.
Although AXL itself is not thought to be a potent oncogenic driver, overexpression of AXL is …
Although AXL itself is not thought to be a potent oncogenic driver, overexpression of AXL is …
AXL receptor as an emerging molecular target in colorectal cancer
L De Rosa, R Di Stasi, V Fusco, LD D'Andrea - Drug Discovery Today, 2024 - Elsevier
Highlights•Several lines of preclinical evidence link the Axl/Gas6 protein system to colorectal
cancer.•Axl overexpression is a negative prognostic factor in colorectal cancer.•Drugs …
cancer.•Axl overexpression is a negative prognostic factor in colorectal cancer.•Drugs …
[HTML][HTML] MERTK inhibition as a targeted novel cancer therapy
KM Tanim, A Holtzhausen, A Thapa, JM Huelse… - International Journal of …, 2024 - mdpi.com
In this issue honoring the contributions of Greg Lemke, the Earp and Graham lab teams
discuss several threads in the discovery, action, signaling, and translational/clinical potential …
discuss several threads in the discovery, action, signaling, and translational/clinical potential …
Commercial Route Development Toward PF-07265807, an AXL-MER Inhibitor Oncology Candidate
DJ Critcher, CP Ashcroft, AJ Pettman… - … Process Research & …, 2024 - ACS Publications
Our route scouting efforts toward finding the most efficient construction of PF-07265807
(ARRY-067) in readiness for process development prior to commercial manufacture are …
(ARRY-067) in readiness for process development prior to commercial manufacture are …
Early-Stage Flow Process Development of a Key Intermediate toward PF-07265807, an AXL-MER Inhibitor Oncology Candidate
CT Armstrong, K Grohowalski, G Russell… - … Process Research & …, 2024 - ACS Publications
The application of continuous processing can afford certain advantages during development
and scale-up, such as enhanced risk mitigation of hazardous compounds and reducing both …
and scale-up, such as enhanced risk mitigation of hazardous compounds and reducing both …
[PDF][PDF] Ray Li7, Vivek Subbiah8
T Beck, J McDermott, J Abbruzzese, T Doi, T Hirohashi… - pfizermedical.pfizerpro.com
Background• AXL receptor tyrosine kinase (AXL) and Mer proto-oncogene tyrosine kinase
(MERTK) are members of the tumor-associated macrophage kinases (TAMK) family and …
(MERTK) are members of the tumor-associated macrophage kinases (TAMK) family and …